Chinese- REPORT SUMMARY
- TABLE OF CONTENTS
-
The report details the trend, potential and market size of CAR T-Cell Therapy for Multiple Myeloma market, and analyzes the current situation and prospects of the market from both qualitative and quantitative aspects, which can be roughly divided into three parts.
The first part (Chapter1-7) mainly covers the qualitative analysis of CAR T-Cell Therapy for Multiple Myelomamarket, defines the market attractiveness level of CAR T-Cell Therapy for Multiple Myeloma market through Porter's Five Forces Analysis, and summarizes the different factors in the overall environment through PEST analysis. Understand the distribution of industrial chain value in each link of industrial chain through the analysis of industrial chain structure. Thus estimate the market space of each link.
The second part (Chapter8-12), based on the segmentation of CAR T-Cell Therapy for Multiple Myeloma industry, describes the types of CAR T-Cell Therapy for Multiple Myeloma market, the applications of major players and the market size, and deeply analyzes the current situation of the global CAR T-Cell Therapy for Multiple Myeloma market and the development prospects and opportunities of CAR T-Cell Therapy for Multiple Myeloma industry.
The third part (Chapter14-15) includes the market positions of the major players and information on the market participants, which will help you gain a comprehensive understanding of the current competitive situation and potential growth opportunities in the market.
As COVID-19 continues to impact the global economy in 2022, the report also considers the short - and long-term impacts of COVID-19 on the global CAR T-Cell Therapy for Multiple Myeloma market in Chapter 13.
By Player:
Collectis
Novartis
Kite Pharma
Juno Therapeutics
By Type:
Monotherapy
Combination Therapy
By End-User:
Multiple Myeloma
Refractory or Relapsed Multiple Myeloma
By Geography:
-
United States
-
Europe
-
China
-
Japan
-
India
-
South Korea
TABLE OF CONTENT
1 Introduction
-
1.1 Market Definition
-
1.2 Market Segment Analysis
-
1.3 Market Size 2022
-
1.4 CAR T-Cell Therapy for Multiple Myeloma Market Outlook: Forecast for 2022 - 2028
-
1.5 Pricing Analysis
2 Executive Summary
3 CAR T-Cell Therapy for Multiple Myeloma Market Lineage Outlook
-
3.1 Parent Market Outlook
-
3.2 Related/Ancillary Market Outlook
-
3.3 Penetration & Growth Prospect Mapping, 2022
4 Market Analysis Tools: Porter's Five Forces
-
4.1 Supplier Power
-
4.2 Buyer Power
-
4.3 Substitution Threat
-
4.4 Threat of New Entrants
-
4.5 Competitive Rivalry
5 CAR T-Cell Therapy for Multiple Myeloma Industry Analysis - PEST (Political & Legal, Economic, Social, and Technological)
-
5.1 Political/Legal Landscape
-
5.2 Economic Landscape
-
5.3 Social Landscape
-
5.4 Technology Landscape
6 CAR T-Cell Therapy for Multiple Myeloma Market - Value Chain Analysis
-
6.1 Industry's Value Chain Analysis
-
6.2 Product Life Cycle
-
6.3 User Perspective Analysis
7 Region and Country-wise CAR T-Cell Therapy for Multiple Myeloma Market Analysis and Outlook to 2022
-
7.1 Global CAR T-Cell Therapy for Multiple Myeloma Consumption (2017-2022)
-
7.2 United States CAR T-Cell Therapy for Multiple Myeloma Consumption (2017-2022)
-
7.3 Europe CAR T-Cell Therapy for Multiple Myeloma Consumption (2017-2022)
-
7.4 China CAR T-Cell Therapy for Multiple Myeloma Consumption (2017-2022)
-
7.5 Japan CAR T-Cell Therapy for Multiple Myeloma Consumption (2017-2022)
-
7.6 India CAR T-Cell Therapy for Multiple Myeloma Consumption (2017-2022)
-
7.7 South Korea CAR T-Cell Therapy for Multiple Myeloma Consumption (2017-2022)
8 Region and Country-wise CAR T-Cell Therapy for Multiple Myeloma Market Analysis and Outlook to 2028
-
8.1 Global CAR T-Cell Therapy for Multiple Myeloma Consumption Forecast (2022-2028)
-
8.2 United States CAR T-Cell Therapy for Multiple Myeloma Consumption Forecast (2022-2028)
-
8.3 Europe CAR T-Cell Therapy for Multiple Myeloma Consumption Forecast (2022-2028)
-
8.4 China CAR T-Cell Therapy for Multiple Myeloma Consumption Forecast (2022-2028)
-
8.5 Japan CAR T-Cell Therapy for Multiple Myeloma Consumption Forecast (2022-2028)
-
8.6 India CAR T-Cell Therapy for Multiple Myeloma Consumption Forecast (2022-2028)
-
8.7 South Korea CAR T-Cell Therapy for Multiple Myeloma Consumption Forecast (2022-2028)
9 Global CAR T-Cell Therapy for Multiple Myeloma Market Outlook by Types and Applications to 2022
-
9.1 Global CAR T-Cell Therapy for Multiple Myeloma Consumption and Growth Rate by Type (2017-2022)
-
9.1.1 Global Monotherapy Consumption and Growth Rate (2017-2022)
-
9.1.2 Global Combination Therapy Consumption and Growth Rate (2017-2022)
-
9.2 Global CAR T-Cell Therapy for Multiple Myeloma Consumption and Growth Rate by Application (2017-2022)
-
9.2.1 Global Multiple Myeloma Consumption and Growth Rate (2017-2022)
-
9.2.2 Global Refractory or Relapsed Multiple Myeloma Consumption and Growth Rate (2017-2022)
10 Global CAR T-Cell Therapy for Multiple Myeloma Market Outlook by Types and Applications to 2028
-
10.1 Global CAR T-Cell Therapy for Multiple Myeloma Consumption Forecast and Growth Rate by Type (2022-2028)
-
10.1.1 Global Monotherapy Consumption Forecast and Growth Rate (2022-2028)
-
10.1.2 Global Combination Therapy Consumption Forecast and Growth Rate (2022-2028)
-
10.2 Global CAR T-Cell Therapy for Multiple Myeloma Consumption Forecast and Growth Rate by Application (2022-2028)
-
10.2.1 Global Multiple Myeloma Consumption Forecast and Growth Rate (2022-2028)
-
10.2.2 Global Refractory or Relapsed Multiple Myeloma Consumption Forecast and Growth Rate (2022-2028)
11 Global CAR T-Cell Therapy for Multiple Myeloma Import and Export Analysis (Top 5 Countries)
-
11.1 Global CAR T-Cell Therapy for Multiple Myeloma Import by Region (Top 5 Countries) (2017-2028)
-
11.2 Global CAR T-Cell Therapy for Multiple Myeloma Export by Region (Top 5 Countries) (2017-2028)
12 Coronavirus Disease (COVID-19) Impact
-
12.1 Industry Impact Analysis
-
12.2 CAR T-Cell Therapy for Multiple Myeloma Market Outlook to 2028 - COVID-19 Affected Forecasts
13 Competition Matrix
-
13.1 Target Markets
-
13.2 Comprehensive Analysis of Products in Competitive Markets
14 Global CAR T-Cell Therapy for Multiple Myeloma Market Competitive Analysis
-
14.1 Collectis
-
14.1.1 Collectis Company Details
-
14.1.2 Collectis CAR T-Cell Therapy for Multiple Myeloma Sales, Price, Value and Gross Profit (2017-2022)
-
14.1.3 Collectis CAR T-Cell Therapy for Multiple Myeloma Product and Service
-
14.2 Novartis
-
14.2.1 Novartis Company Details
-
14.2.2 Novartis CAR T-Cell Therapy for Multiple Myeloma Sales, Price, Value and Gross Profit (2017-2022)
-
14.2.3 Novartis CAR T-Cell Therapy for Multiple Myeloma Product and Service
-
14.3 Kite Pharma
-
14.3.1 Kite Pharma Company Details
-
14.3.2 Kite Pharma CAR T-Cell Therapy for Multiple Myeloma Sales, Price, Value and Gross Profit (2017-2022)
-
14.3.3 Kite Pharma CAR T-Cell Therapy for Multiple Myeloma Product and Service
-
14.4 Juno Therapeutics
-
14.4.1 Juno Therapeutics Company Details
-
14.4.2 Juno Therapeutics CAR T-Cell Therapy for Multiple Myeloma Sales, Price, Value and Gross Profit (2017-2022)
-
14.4.3 Juno Therapeutics CAR T-Cell Therapy for Multiple Myeloma Product and Service
15 Appendix
TABLE OF CHARTS
-
Table Definition of CAR T-Cell Therapy for Multiple Myeloma
-
Figure CAR T-Cell Therapy for Multiple Myeloma Picture
-
Table Global CAR T-Cell Therapy for Multiple Myeloma Market Size and Forecast 2022 - 2028 (USD million)
-
Figure Global CAR T-Cell Therapy for Multiple Myeloma Market Size and Forecast 2022 - 2028 (USD million)
-
Figure Global CAR T-Cell Therapy for Multiple Myeloma Market: Year-over-year Growth 2022 - 2028 (%)
-
Table Parent Market Analysis
-
Figure Parent Market Price
-
Table Related/Ancillary Market Outlook Analysis
-
Table Supplier Power Analysis
-
Table Buyer Power Analysis
-
Table Substitution Threat Analysis
-
Table Threat of New Entrants Analysis
-
Table Competitive Rivalry Analysis
-
Figure Global CAR T-Cell Therapy for Multiple Myeloma Consumption by Country (2017-2022)
-
Figure United States CAR T-Cell Therapy for Multiple Myeloma Consumption and Growth Rate (2017-2022)
-
Table Europe CAR T-Cell Therapy for Multiple Myeloma Consumption and Growth Rate (2017-2022)
-
Figure China CAR T-Cell Therapy for Multiple Myeloma Consumption and Growth Rate (2017-2022)
-
Figure Japan CAR T-Cell Therapy for Multiple Myeloma Consumption and Growth Rate (2017-2022)
-
Figure India CAR T-Cell Therapy for Multiple Myeloma Consumption and Growth Rate (2017-2022)
-
Figure South Korea CAR T-Cell Therapy for Multiple Myeloma Consumption and Growth Rate (2017-2022)
-
Figure Global CAR T-Cell Therapy for Multiple Myeloma Consumption Forecast by Country (2022-2028)
-
Figure United States CAR T-Cell Therapy for Multiple Myeloma Consumption Forecast and Growth Rate (2022-2028)
-
Table Europe CAR T-Cell Therapy for Multiple Myeloma Consumption Forecast and Growth Rate (2022-2028)
-
Figure China CAR T-Cell Therapy for Multiple Myeloma Consumption Forecast and Growth Rate (2022-2028)
-
Figure Japan CAR T-Cell Therapy for Multiple Myeloma Consumption Forecast and Growth Rate (2022-2028)
-
Figure India CAR T-Cell Therapy for Multiple Myeloma Consumption Forecast and Growth Rate (2022-2028)
-
Figure South Korea CAR T-Cell Therapy for Multiple Myeloma Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Monotherapy Consumption and Growth Rate (2017-2022)
-
Figure Global Combination Therapy Consumption and Growth Rate (2017-2022)
-
Figure Global Multiple Myeloma Consumption and Growth Rate (2017-2022)
-
Figure Global Refractory or Relapsed Multiple Myeloma Consumption and Growth Rate (2017-2022)
-
Figure Global Monotherapy Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Combination Therapy Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Multiple Myeloma Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Refractory or Relapsed Multiple Myeloma Consumption Forecast and Growth Rate (2022-2028)
-
Table Global CAR T-Cell Therapy for Multiple Myeloma Import by Region (Top 5 Countries) (2017-2028)
-
Table Global CAR T-Cell Therapy for Multiple Myeloma Export by Region (Top 5 Countries) (2017-2028)
-
Table Collectis (Foundation Year, Company Profile and etc.)
-
Table Collectis CAR T-Cell Therapy for Multiple Myeloma Sales, Price, Value and Gross Profit (2017-2022)
-
Table Collectis CAR T-Cell Therapy for Multiple Myeloma Product and Service
-
Table Novartis (Foundation Year, Company Profile and etc.)
-
Table Novartis CAR T-Cell Therapy for Multiple Myeloma Sales, Price, Value and Gross Profit (2017-2022)
-
Table Novartis CAR T-Cell Therapy for Multiple Myeloma Product and Service
-
Table Kite Pharma (Foundation Year, Company Profile and etc.)
-
Table Kite Pharma CAR T-Cell Therapy for Multiple Myeloma Sales, Price, Value and Gross Profit (2017-2022)
-
Table Kite Pharma CAR T-Cell Therapy for Multiple Myeloma Product and Service
-
Table Juno Therapeutics (Foundation Year, Company Profile and etc.)
-
Table Juno Therapeutics CAR T-Cell Therapy for Multiple Myeloma Sales, Price, Value and Gross Profit (2017-2022)
-
Table Juno Therapeutics CAR T-Cell Therapy for Multiple Myeloma Product and Service
-
